Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021
JAMA · 2023
DOI: 10.1001/jama.2022.19691 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von William B Feldman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Economic Competition, Nebulizers and Vaporizers, Patents as Topic, Drug Industry. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study quantifies the revenue earned on all brand-name inhalers approved by the US Food and Drug Administration from 2000 to 2021 and compared earnings before and after expiration of primary patents on these products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
- West Virginia University College of Law, Morgantown.
- University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.
- Department of Health Policy, London School of Economics and Political Science, London, England.
Zitieren
APA
Feldman, W. B., Tu, S. S., Alhiary, R., Kesselheim, A. S., & Wouters, O. J. (2023). Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021. JAMA. https://doi.org/10.1001/jama.2022.19691
Vancouver
Feldman WB, Tu SS, Alhiary R, Kesselheim AS, Wouters OJ. Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021. JAMA. 2023. doi:10.1001/jama.2022.19691
BibTeX
@article{Feldman2023,
author = {Feldman, William B and Tu, S Sean and Alhiary, Rasha and Kesselheim, Aaron S and Wouters, Olivier J},
title = {Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2022.19691}
}
EUVIMED